Recent NRBO News
- NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 06/26/2024 01:06:00 PM
- NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/25/2024 09:08:00 PM
- NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/24/2024 12:01:00 PM
- NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models • PR Newswire (US) • 06/22/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 11:26:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:06:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:30:16 PM
- NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone • PR Newswire (US) • 05/22/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:05:51 PM
- NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/09/2024 12:01:00 PM
- NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June • PR Newswire (US) • 04/30/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 04/17/2024 12:05:00 PM
- NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 04/01/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/28/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 03/13/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer • PR Newswire (US) • 03/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:14 PM
- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/29/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:52:22 PM
- NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference • PR Newswire (US) • 02/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:15 PM
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/01/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:23 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM